Mediwound Ltd
NASDAQ:MDWD
Mediwound Ltd
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Clinical focus: EscharEx Phase III VALUE trial enrolling; company targets 216 patients with a prespecified interim assessment and full enrollment by year-end 2026.
Program expansion: EscharEx development is being expanded into diabetic foot ulcers (Phase II planned H2 2026) and an investigator-led pressure ulcer study (H2 2026).
Collaborations: Multiple industry partners (including B. Braun, Coloplast, ConvaTec, Essity, Molnlycke, Solventum, MiMedx) are participating in clinical programs, supplying standard-of-care products and validating the program.
NexoBrid capacity: Expanded manufacturing facility is operational with sixfold capacity increase; commercial release from that site is subject to regulatory approvals expected in 2026.
Government support: Revenue guidance and planning assume continued support from BARDA and the U.S. Department of War (Department of War funding to date: $18.2 million).
2025 financials & balance sheet: Full-year 2025 revenue was $17 million (down from $20.2M), cash and equivalents $53.6 million (up from $43.6M); company completed a $30 million registered direct offering plus $3.5 million from warrant exercises.
Guidance: MediWound reaffirmed multiyear revenue guidance: $24M–$26M (2026), $32M–$35M (2027), $50M–$55M (2028), assuming BARDA/DOD support and regulatory milestones.
